Fischer’s Nanyang Biologics joins Nvidia, HPE, Equinix to build AI-driven drug discovery platform
The platform integrates machine learning, virtual screening, metagenomics, and metaproteomics to identify potential drug candidates rapidly.
Fischer Medical Ventures’ sister concern, Nanyang Biologics (NYB), has entered a strategic collaboration with Nvidia, Hewlett Packard Enterprise (HPE), and Equinix to develop Vecura, an AI-powered drug discovery platform.
Vecura combines predictive models with a proprietary library of millions of natural compounds, aiming to shorten therapeutic discovery timelines from the traditional 10–12 years to just a few hours.
Anchored in Singapore, the platform will be supported by Nvidia, HPE, and Equinix to co-develop what is positioned as the world’s largest AI-curated compound library.
The platform integrates machine learning, virtual screening, metagenomics, and metaproteomics to identify potential drug candidates rapidly. It draws from a natural compound library sourced from tropical flora, intending to accelerate the development of pharmaceuticals, dietary supplements, functional foods, and personal care products.
Nutraceutical pipeline and academic support
Beyond drug discovery, NYB is working to build a pipeline of evidence-based nutraceuticals using its AI-powered platform and compound library. Among them is CareViva NS, a longevity-focused formulation developed from traditional herbs, involving contributions from over 26 scientists and professors from Nanyang Technological University, Singapore.
Ravindran Govindan, executive chairman & managing director of FMV, said, “With the strong support of world-class companies like Nvidia, HPE, and Equinix, NYB’s supercharged Vecura platform will unleash the powerful therapeutic potential of nature with AI and discover millions of valuable natural compounds in shorter time to enable any Biotech companies to use to develop their health and wellness products faster.”
